Fig. 2From: A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug ActFew rare diseases account for a large percentage of orphan drug designations and initial orphan drug approvals, 1983–2022Back to article page